MDLN — More sales and the profit question

Selling more medical supplies does not automatically mean earning more on the bottom line.

On November 4, $MDLN reported third-quarter sales of $7.9 billion, up 10.4% from a year earlier. Yet net income slipped to $318 million from $322 million. Medline cited higher inventory costs associated with inflation, operating expenses and customer mix, partly offset by higher sales and tariff-refund benefits.

The company supplies medical products and supports healthcare customers with distribution. It raised its forecast for full-year organic sales growth to 10%–10.5%, from 9%–10%. That is management's expectation, not revenue already earned. Adjusted earnings before interest, taxes, depreciation and amortization rose 11.8% to $960 million in the quarter, a different measure from net income.

The open question is whether new customer business can grow without the costs of serving it absorbing too much of the benefit. Watch future sales growth alongside gross profit margin and reported net income. Also check management's updates on its distribution network: capacity investment can support more customers, but it must eventually pay for itself.